International Medicine and Health Guidance News ›› 2022, Vol. 28 ›› Issue (3): 357-360.DOI: 10.3760/cma.j.issn.1007-1245.2022.03.015

• Laboratory Medicine Column • Previous Articles     Next Articles

Meta-analysis of value of serum thymidine kinase 1 in diagnosis of thyroid cancer

Liu Huixuan, He Yajun   

  1. Clinical Laboratory, Guangzhou Red Cross Hospital, Jinan University, Guangzhou 510220, China
  • Received:2021-10-19 Online:2022-02-01 Published:2022-03-01
  • Contact: He Yajun, Email: heyajun0801@163.com

血清胸苷激酶1对甲状腺癌诊断价值的meta分析

刘慧轩  何雅军   

  1. 暨南大学附属广州红十字会医院检验科,广州 510220
  • 通讯作者: 何雅军,Email:heyajun0801@163.com

Abstract: Objective To investigate the value of serum thymidine kinase 1 (S-TK1) in the diagnosis of thyroid cancer. Methods The relevant literatures on S-TK1 in the diagnosis of thyroid cancer were searched and collected from PubMed, Web of Science, CNKI, VIP, Wanfang Database, and other databases from their establishment to April 2021. Meta-analysis was performed using Metadisc 1.4 and RevMan 5.3. Summary receiver operating characteristic curve plan and Spearman correlation coefficient were used to evaluate the threshold effect. Cochrane-Q test and I2 test were used for heterogeneity analysis. The random effect model was used for meta-analysis. Results Eight literatures met the inclusion criteria, including 820 cases of thyroid cancer and 831 cases normal or of benign thyroid tumors. Heterogeneity exists between the studies. The calculation based on the random effect model showed that the total sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and summary receiver operating character curve area under curve were 73% (95%CI 0.70-0.76, 601/820), 75% (95%CI 0.72-0.78, 624/831), 3.63 (95%CI 2.24-5.90), 0.34 (95%CI 0.25-0.45), and 0.84, respectively. Conclusion S-TK1 is effective in the diagnosis of thyroid cancer, which is beneficial to the early detection and diagnosis of thyroid cancer, and has certain clinical guiding significance in the diagnosis of thyroid cancer.

Key words: Thyroid cancer, Serum thymidine kinase 1, Meta-analysis

摘要: 目的 探讨血清胸苷激酶1(serum thymidine kinase 1,S-TK1)在甲状腺癌诊断中的价值。方法 在PubMed、Web of Science、知网、维普、万方等数据库检索S-TK1诊断甲状腺癌的文献,检索年限从建库至2021年4月。应用MetaDiSc 1.4及RevMan 5.3进行meta分析。采用总受试者工作特征曲线平面图及Spearman相关系数评估阈值效应。异质性分析采用Cochrane-Q检验和I2检验。使用随机效应模型进行meta分析。结果 8篇文献符合纳入标准,其中甲状腺癌患者820例,正常或甲状腺良性肿瘤共831例。各研究之间存在异质性,按照随机效应模型计算,汇总灵敏度、特异度、阳性似然比、阴性似然比、受试者工作特征曲线下面积分别是73%(95%CI 0.70~0.76,601/820)、75%(95%CI 0.72~0.78,624/831)、3.63(95%CI 2.24~5.90)、0.34(95%CI 0.25~0.45)、0.84。结论 S-TK1诊断甲状腺癌的效能较好,有利于早期发现和诊断甲状腺癌,对甲状腺癌诊断有一定的临床指导意义。

关键词: 甲状腺癌,  , 血清胸苷激酶1, meta分析